Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE‐PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution

BACKGROUND: Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de-facto standard-of-care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late-effects. We aimed to describe the single institution experience of using both regimens in patients with pediatric HL. METHODS: This retrospective cohort study evaluated a total of 224 patients diagnosed with HL between 1999 and 2018 at Children’s Hospital Los Angeles (CHLA), of which 93 patients were eligible having received ABVD (n=46) or ABVE-PC (n=47) chemotherapy as their initial treatment. Descriptive analyses were performed using the Student’s t-test or Fisher’s exact test. Survival analysis used the Kaplan-Meier method. Events included death, relapse and secondary malignancy. We also describe the use of radiation therapy, pulmonary toxicity and cardiomyopathy determined by shortening fraction